Perrigo (PRGO) vs Palvella Therapeutics (PVLA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Perrigo (PRGO) over the past year, gaining 75.5% versus a loss of 33.0%. Over five years, PVLA leads with a -63.6% price change compared with -67.6% for PRGO. Perrigo is the larger company by market cap ($2.06 billion vs $1.94 billion), about 1.1 times the size.
Perrigo pays a dividend yielding 7.79%, while Palvella Therapeutics does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | PVLA |
|---|---|---|
| Share price | $14.90 | $134.93 |
| Market cap | $2.06B | $1.94B |
| 1-day change | +2.76% | +2.73% |
| YTD return | +4.17% | +25.48% |
| 1-year return | -33.03% | +75.47% |
| 5-year return | -67.58% | -63.60% |
| Forward P/E | 6.21 | — |
| EPS (TTM) | $-12.28 | $-4.85 |
| Dividend yield | 7.79% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| Revenue (latest FY) | $4.25B | — |
| Revenue growth (YoY) | -2.75% | — |
| Net income (latest FY) | $-1.43B | $-41.72M |
| Gross margin | 35.14% | — |
| Operating margin | -26.39% | — |
| Net margin | -33.51% | — |
| 52-week high | $22.02 | $161.38 |
| 52-week low | $9.23 | $65.93 |
| Distance from 52-week high | -32.33% | -16.39% |
| Analyst consensus | none | none |
| Avg. price target upside | +10.74% | +70.85% |
| Average volume | 2.80M | 211.36K |
| Shares outstanding | 138.37M | 14.41M |
| Employees | 8,100 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed PRGO by 108.5 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (7.79% vs 0.00%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
PRGO vs PVLA FAQ
Which is bigger, Perrigo or Palvella Therapeutics?
Perrigo (PRGO) is larger, with a market capitalization of $2.06B compared with $1.94B for Palvella Therapeutics (PVLA).
Which stock has performed better over the past year, PRGO or PVLA?
PVLA returned +75.47% over the past 12 months, compared with -33.03% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or Palvella Therapeutics?
Perrigo pays a dividend yielding 7.79%, while Palvella Therapeutics does not currently pay a regular dividend.
Are Perrigo and Palvella Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.